Transforming the management of dermatologic cancers.
Castle Biosciences is a skin cancer diagnostics company focused on providing physicians and patients with personalized, clinically actionable genomic information enabling more accurate treatment plan decisions. From its formation in 2008, Castle Biosciences has applied emerging artificial intelligence techniques in molecular diagnostics to improve patient care and outcomes. Our DecisionDx family of molecular diagnostic tests have the ability to meaningfully impact how cancers are diagnosed and managed (castletestinfo.com).
Castle Biosciences has active research and development programs for tests in other dermatologic diseases with high clinical need, including in patients with moderate to severe psoriasis, atopic dermatitis and related conditions. The company is based in Friendswood, Texas with laboratory operations in Phoenix, Arizona (www.CastleBiosciences.com).
Brands: DecisionDx-Melanoma, DecisionDx-UM, DecisionDx-SCC, DiffDx-Melanoma & myPath Melanoma